NYSE:MD

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

MEDNAX, Inc., together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology and teleradiology, pediatric cardiology, and other pediatric subspecialty physician services in the United States and Puerto Rico.


Snowflake Analysis

Fair value with moderate growth potential.


Similar Companies

Share Price & News

How has MEDNAX's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: MD's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-0.2%

MD

0.9%

US Healthcare

-0.04%

US Market


1 Year Return

-5.4%

MD

17.8%

US Healthcare

17.1%

US Market

Return vs Industry: MD underperformed the US Healthcare industry which returned 17.8% over the past year.

Return vs Market: MD underperformed the US Market which returned 17.1% over the past year.


Shareholder returns

MDIndustryMarket
7 Day-0.2%0.9%-0.04%
30 Day12.6%6.4%5.1%
90 Day51.3%9.0%19.5%
1 Year-5.4%-5.4%19.4%17.8%19.6%17.1%
3 Year-51.5%-51.5%35.5%29.5%42.5%33.3%
5 Year-75.9%-75.9%46.8%36.6%75.1%56.2%

Price Volatility Vs. Market

How volatile is MEDNAX's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is MEDNAX undervalued compared to its fair value and its price relative to the market?

45.8%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: MD ($20.3) is trading below our estimate of fair value ($37.45)

Significantly Below Fair Value: MD is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: MD is unprofitable, so we can't compare its PE Ratio to the US Healthcare industry average.

PE vs Market: MD is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MD's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MD is good value based on its PB Ratio (2.1x) compared to the US Healthcare industry average (3.1x).


Next Steps

Future Growth

How is MEDNAX forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?

88.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MD is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).

Earnings vs Market: MD is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: MD's is expected to become profitable in the next 3 years.

Revenue vs Market: MD's revenue is expected to decline over the next 3 years (-2.2% per year).

High Growth Revenue: MD's revenue is forecast to decline over the next 3 years (-2.2% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: MD's Return on Equity is forecast to be low in 3 years time (18.3%).


Next Steps

Past Performance

How has MEDNAX performed over the past 5 years?

-58.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MD is currently unprofitable.

Growing Profit Margin: MD is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MD is unprofitable, and losses have increased over the past 5 years at a rate of 58.7% per year.

Accelerating Growth: Unable to compare MD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MD is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (21.8%).


Return on Equity

High ROE: MD has a negative Return on Equity (-145.04%), as it is currently unprofitable.


Next Steps

Financial Health

How is MEDNAX's financial position?


Financial Position Analysis

Short Term Liabilities: MD's short term assets ($688.3M) exceed its short term liabilities ($383.9M).

Long Term Liabilities: MD's short term assets ($688.3M) do not cover its long term liabilities ($2.2B).


Debt to Equity History and Analysis

Debt Level: MD's debt to equity ratio (210.2%) is considered high.

Reducing Debt: MD's debt to equity ratio has increased from 58.3% to 210.2% over the past 5 years.

Debt Coverage: MD's debt is not well covered by operating cash flow (19%).

Interest Coverage: MD is unprofitable, therefore interest payments are not well covered by earnings.


Balance Sheet


Next Steps

Dividend

What is MEDNAX current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate MD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MD's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MD's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MD's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure


CEO

Mark Ordan (61 yo)

0.083

Tenure

Mr. Mark S. Ordan serves as Chief Executive Officer and Director at MEDNAX, Inc. since July 12, 2020. He had been an Independent Director of VEREIT, Inc., sole general Partner of VEREIT Operating Partnersh ...


Leadership Team

NamePositionTenureCompensationOwnership
Roger Medel
Co-Founder & Director41.58yrsUS$8.07m2.02%
$ 34.3m
Stephen Farber
Executive VP & CFO1.75yrsUS$3.40m0.33%
$ 5.6m
John Pepia
Senior VP & Chief Accounting Officer4.25yrsUS$2.07m0.13%
$ 2.2m
Dominic Andreano
Executive VP8.25yrsUS$1.89m0.090%
$ 1.5m
Mark Ordan
CEO & Director0.083yrno data0.078%
$ 1.3m
Charles Lynch
Vice President of Strategy & Investor Relationsno datano datano data
Mary Ann Moore
Senior VP1.58yrsno datano data
James Swift
Chief Development Officer6.67yrsno datano data
Claire Fair
Senior VP & Chief Human Resources Officer1.58yrsno datano data
Nikos Nikolopoulos
Executive VP and Chief Strategy & Growth Officer1.17yrsno data0.098%
$ 1.7m
Matthew Devine
President of Radiology Solutions0.58yrno datano data
Michael Pokroy
Regional President of Pacific Region18.58yrsno datano data

1.8yrs

Average Tenure

57yo

Average Age

Experienced Management: MD's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Roger Medel
Co-Founder & Director41.58yrsUS$8.07m2.02%
$ 34.3m
Mark Ordan
CEO & Director0.083yrno data0.078%
$ 1.3m
Paul Gabos
Independent Director17.75yrsUS$220.01k0.029%
$ 493.5k
Waldemar Carlo
Independent Director21.17yrsUS$210.01k0.038%
$ 645.6k
Guy Sansone
Independent Chairman0.083yrno data0.031%
$ 520.3k
Thomas McEachin
Independent Director0.083yrno data0.014%
$ 242.7k
Manuel Kadre
Lead Independent Director6.42yrsUS$235.01k0.15%
$ 2.5m
Karolyn Barker
Independent Director5.25yrsUS$200.01k0.021%
$ 360.9k
John Starcher
Independent Director0.083yrno data0.014%
$ 242.6k
Shirley Weis
Independent Director0.083yrno data0.015%
$ 250.4k
Gavin Molinelli
Board Observer0.083yrno datano data
Michael Rucker
Independent Director1.25yrsUS$245.42k0.018%
$ 313.8k

0.7yrs

Average Tenure

55yo

Average Age

Experienced Board: MD's board of directors are not considered experienced ( 0.7 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

MEDNAX, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: MEDNAX, Inc.
  • Ticker: MD
  • Exchange: NYSE
  • Founded: 1979
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: US$1.700b
  • Shares outstanding: 83.74m
  • Website: https://www.mednax.com

Number of Employees


Location

  • MEDNAX, Inc.
  • 1301 Concord Terrace
  • Sunrise
  • Florida
  • 33323
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MDNYSE (New York Stock Exchange)YesCommon StockUSUSDSep 1995
PDCDB (Deutsche Boerse AG)YesCommon StockDEEURSep 1995
MD *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNSep 1995

Biography

MEDNAX, Inc., together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology and teleradiology, pediatric cardiology, and other pediatric subspecialty physician services in the Uni ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/08/13 00:17
End of Day Share Price2020/08/12 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.